logo
Ousted FDA vaccine chief Vinay Prasad is returning to the agency

Ousted FDA vaccine chief Vinay Prasad is returning to the agency

WASHINGTON — A Food and Drug Administration official is getting his job back as the agency's top vaccine regulator, less than two weeks after he was pressured to step down at the urging of biotech executives, patient groups and conservative allies of President Donald Trump.
Dr. Vinay Prasad is resuming leadership of the FDA center that regulates vaccines and biotech therapies, a spokesperson for the Department of Health and Human Services said in a statement Monday.
Prasad left the agency late last month after drawing ire of right-wing activists, including Laura Loomer, because of his past statements criticizing Trump.
A longtime a critic of FDA's standards for approving medicines, Prasad briefly ordered the maker of a gene therapy for Duchenne's muscular dystrophy to halt shipments after two patient deaths. But that action triggered pushback from the families of boys with the fatal condition and libertarian supporters of increased access to experimental medicines.
Prasad's decision to pause the therapy was criticized by The Wall Street Journal editorial board, former Republican Sen. Rick Santorum and others. The FDA swiftly reversed its decision suspending the therapy's use.
Loomer posted online that Prasad was 'a progressive leftist saboteur,' noting his history of praising liberal independent Sen. Bernie Sanders.
But Prasad has had the backing of FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr., who have both called for scrutinizing the use of COVID-19 vaccines. Under Prasad, the FDA restricted the approval of two new COVID-19 shots from vaccine makers Novavax and Moderna and set stricter testing requirements for future approvals.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tennis star Monica Seles diagnosed with myasthenia gravis. What is it?
Tennis star Monica Seles diagnosed with myasthenia gravis. What is it?

Yahoo

time13 minutes ago

  • Yahoo

Tennis star Monica Seles diagnosed with myasthenia gravis. What is it?

Tennis legend Monica Seles is opening up about her journey with myasthenia gravis, a neuromuscular autoimmune disease she was diagnosed with three years ago. In a recent interview with The Associated Press, Seles, 51, said she chose to share her diagnosis ahead of the U.S. Open later this month to raise awareness about the disease, also known as MG. Myasthenia gravis affects about 20 out of every 100,000 people in the world, according to the Cleveland Clinic. "The actual number may be higher, as some people with mild cases may not know they have the condition," the clinic notes. "In the United States, there are approximately 60,000 people affected by myasthenia gravis at any given time." Seles, whose career included nine Grand Slam titles and a place in the International Tennis Hall of Fame, said it took time to process the diagnosis. "It took me quite some time to really absorb it, speak openly about it, because it's a difficult one. It affects my day-to-day life quite a lot," she told the AP. Myasthenia gravis symptoms Seles said she was referred to a neurologist after noticing symptoms such as double vision and weakness in her arms and legs. "I would be playing with some kids or family members, and I would miss a ball. I was like, 'Yeah, I see two balls.' These are obviously symptoms that you can't ignore," Seles said, adding even blowing out her hair "became very difficult." In addition to eyes, arms and legs, myasthenia gravis can target muscles in the face and neck, according to the Cleveland Clinic, with symptoms that include: Muscle weakness and fatigueDroopy eyelidsBlurry or double visionLimited facial expressionsDifficulty speaking, swallowing or chewingTrouble walking Muscles usually get weaker when someone is active and strengthen when they rest, the clinic adds. What causes myasthenia gravis? The autoimmune form of MG happens when the body's immune system mistakenly attacks itself, the Cleveland Clinic says. It is unclear why this happens. "Studies suggest that certain immune system cells in your thymus gland have trouble identifying what's a threat to your body (like bacteria or viruses) versus healthy components," the clinic adds. While the disease can affect people of any age, the Mayo Clinic notes it is more common in women younger than 40 and in men older than 60. Myasthenia gravis treatment There is no cure for myasthenia gravis, although treatment can help with symptoms. Treatment options include medications, thymus gland removal surgery, lifestyle changes and more, according to the National Institute of Neurological Disorders and Stroke. "Some cases of myasthenia gravis may go into remission, either temporarily or permanently and muscle weakness may disappear completely," the institute added. Trump says he's placing D.C. police under federal control, deploying National Guard Jamie Lee Curtis: The 60 Minutes Interview What will National Guard troops do in Washington, D.C.? Solve the daily Crossword

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today

Yahoo

time13 minutes ago

  • Yahoo

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today

Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store